Hansa Biopharma AB HNSA

STO: HNSA | ISIN: SE0002148817   27/06/2025
26,94 SEK (+5,15%)
(+5,15%)   27/06/2025

14 mei 2025 · Hansa Biopharma data at the 2025 PNS Annual Meeting demonstrates potential of imlifidase in the treatment of GBS · Persbericht

13 mei 2025 · Hansa Biopharma appoints Maria Törnsén as Chief Operating Officer and President U.S. · Persbericht

24 april 2025 · Hansa Biopharma Reports First Quarter and Interim January-March 2025 Financial Results · Persbericht

21 maart 2025 · Hansa Biopharma publishes 2024 Annual and Sustainability Reports · Persbericht

11 maart 2025 · Hansa Biopharma completes enrolment in European Phase 3 20-HMedIdeS-19 Post Authorization Efficacy and Safety study in highly sensitized kidney transplant patients · Persbericht

5 september 2024 · Hansa Biopharma to Participate in H.C. Wainwright 26th Annual Global Investment Conference · Persbericht

23 augustus 2024 · Hansa Biopharma Announces Departure of Chief Commercial Officer, Matthew Shaulis · Persbericht

18 juli 2024 · Hansa Biopharma Reports Second Quarter 2024 Financial Results and Business Update · Persbericht

3 juli 2024 · Hansa Biopharma to host Q2 2024 interim results conference call · Persbericht

28 juni 2024 · Hansa Biopharma: increase in number of shares and votes · Persbericht

31 mei 2024 · Hansa Biopharma Completes Randomization in Pivotal Phase 3 US ConfIdeS Trial · Persbericht

21 mei 2024 · Hansa Biopharma to present data at 2024 American Transplant Congress annual meeting · Persbericht

3 mei 2024 · Hansa Biopharma: increase in number of shares and votes · Persbericht

18 april 2024 · Hansa Biopharma interim report January-March 2024 · Persbericht

2 april 2024 · Hansa Biopharma Expects Strong First Quarter 2024 Sales Performance · Persbericht

21 maart 2024 · Hansa Biopharma publishes 2023 Annual and Sustainability Reports · Persbericht

22 februari 2024 · Evan Ballantyne to join Hansa Biopharma as Chief Financial Officer · Persbericht

2 februari 2024 · Hansa Biopharma Year-end report January-December 2023 · Persbericht

6 januari 2024 · Hansa Biopharma provides update on business and key financials ahead of the JP Morgan Healthcare Conference · Persbericht

14 december 2023 · Imlifidase met primary endpoint in 16-HMedIdes-12 phase 2 trial in patients with AMR following kidney transplantation · Persbericht

Mijn selecties